A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV)

This is a first-in-human study testing the safety of a dendritic cell vaccine in people with breast cancer (triple-negative or HER2-positive) that has spread to the membranes surrounding the brain and spinal cord — a rare and serious condition called leptomeningeal disease. **You may be eligible if...** - You have triple-negative breast cancer (TNBC) or HER2-positive breast cancer - You have been diagnosed with leptomeningeal disease, confirmed by cancer cells found in spinal fluid or characteristic MRI findings - You show signs or symptoms consistent with leptomeningeal involvement **You may NOT be eligible if...** - You have a different breast cancer subtype (e.g., ER/PR-positive and HER2-negative) - You do not have confirmed leptomeningeal disease - You are too unwell to participate in a Phase I study Talk to your doctor to see if this trial is right for you.